What is the 13F Pro Quality Score for AEMD?

13F Pro ranks AETHLON MEDICAL INC (AEMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AEMD's current score at https://13fpro.ai/research/AEMD (free sign-up required for the full ranking).

Which hedge funds own the most AEMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AEMD include GEODE CAPITAL MANAGEMENT,, Ikarian Capital,, Shay Capital. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AEMD as soon as new 13F filings post.

Where does 13F Pro source AEMD data?

All AETHLON MEDICAL INC fundamentals and ownership data come directly from SEC EDGAR. AETHLON MEDICAL INC files with the SEC under CIK 882291. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AEMD in?

AETHLON MEDICAL INC (AEMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AEMD research updated on 13F Pro?

AEMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AETHLON MEDICAL INC(AEMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 882291 AEMD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AEMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AETHLON MEDICAL INC (AEMD), a Healthcare sector company. AEMD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.6m in revenue. Based on the latest XBRL financial filings (Q4 2026), AETHLON MEDICAL INC reports net income of $-1.9M, free cash flow of $-1.8M. Top institutional holders of AEMD by reported 13-F value include GEODE CAPITAL MANAGEMENT,, Ikarian Capital,, Shay Capital, based on the most recent SEC filings. AEMD trades on the Nasdaq exchange and files with the SEC under CIK 882291. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AEMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AETHLON MEDICAL INC directly from SEC EDGAR.

Net Income

Q4 2026

$-1.9M

Free Cash Flow

Q4 2026

$-1.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2026

FY23 $574.2KFY24 $0.00FY25 —FY26 —

Net Income

+46.6% YoY

$-7.2MFY 2026

FY23 $-12.0MFY24 $-12.2MFY25 $-13.4MFY26 $-7.2M

Operating Income

+21.9% YoY

$-7.3MFY 2026

FY23 $-11.9MFY24 $-12.6MFY25 $-9.3MFY26 $-7.3M

EPS (Diluted)

+87.6% YoY

$-10.61FY 2026

FY23 $-5.86FY24 $-38.87FY25 $-85.77FY26 $-10.61

Total Assets

-13.9% YoY

$6.3MFY 2026

FY23 $17.5MFY24 $8.2MFY25 $7.4MFY26 $6.3M

Op. Cash Flow

+8.5% YoY

$-7.0MFY 2026

FY23 $-10.5MFY24 $-10.1MFY25 $-7.6MFY26 $-7.0M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	—	—	$0.00 -100.0%	$574.2K +95.2%	$294.2K -55.4%	$659.1K
Net Income	$-7.2M +46.6%	$-13.4M -9.7%	$-12.2M -1.5%	$-12.0M -15.5%	$-10.4M -32.1%	$-7.9M
Operating Income	$-7.3M +21.9%	$-9.3M +26.1%	$-12.6M -6.2%	$-11.9M -14.2%	$-10.4M -32.1%	$-7.9M
EPS (Diluted)	$-10.61 +87.6%	$-85.77 -120.7%	$-38.87 -563.3%	$-5.86 -725.4%	$-0.71	—
Total Assets	$6.3M -13.9%	$7.4M -10.8%	$8.2M -52.9%	$17.5M -9.8%	$19.4M +82.0%	$10.7M
Operating Cash Flow	$-7.0M +8.5%	$-7.6M +24.5%	$-10.1M +3.6%	$-10.5M -7.6%	$-9.8M -44.4%	$-6.8M

AI Insight: AEMD Financial Trends

AEMD remains pre-revenue with persistent $2M quarterly operating losses and deteriorating equity base, offering no positive financial inflection.

• Net income losses have stabilized at $1–2M/quarter since Q3 2025, improving from $6M loss in Q1 2025.

• Operating cash flow consistently negative at $2M/quarter across all eight quarters; no FCF generation.

• Shareholder equity has declined 44% from $9M (Q2 2024) to $5M (Q1 2026), signaling ongoing shareholder dilution.

⚠ Revenue remains unreported across all periods; clinical-stage company with no commercial traction evident.

⚠ Runway at current burn rate ($2M quarterly OpEx) and equity trajectory suggests need for capital raise within 2–3 quarters.

AI Insight: AEMD Ratio Trends

Persistent and worsening shareholder value destruction: ROE deteriorated to -154.2% in Q1 2026, worst in dataset; company remains unprofitable with no visible path to positive returns.

• ROE collapsed to -154.2% in Q1 2026 from -120.3% in Q4 2025, marking sharpest quarterly deterioration in 9-month period.

• ROA worsened to -81.2% in Q3 2025 from -90.1% in Q2 2024, indicating sustained asset base erosion amid continued losses.

• No improvement in profitability metrics across entire dataset; all available return ratios remain deeply negative.

⚠ ROE reversal: -103.5% in Q3 2025 briefly suggested stabilization, but Q4–Q1 2026 deterioration signals regression, not inflection.

⚠ Data gaps (missing OpMargin, NPM, ROIC) prevent full profitability assessment; monitor next earnings for margin/cash burn visibility.

Get alerted when AEMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AETHLON MEDICAL INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AEMD

GEODE CAPITAL MANAGEMENT, LLC
$53.4K24,364 sh
Ikarian Capital, LLC
$31.5K14,364 sh
Shay Capital LLC
$30.9K14,124 sh
XTX Topco Ltd
$29.2K13,342 sh
MORGAN STANLEY
$4.5K2,047 sh
Tower Research Capital LLC (TRC)
$3.5K1,611 sh
UBS Group AG
$2.0K895 sh
GROUP ONE TRADING, L.P.
$31.0014 sh
BlackRock, Inc.
$22.0010 sh
Caitong International Asset Management Co., Ltd
$18.008 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$53.4K	24,364
Ikarian Capital, LLC	$31.5K	14,364
Shay Capital LLC	$30.9K	14,124
XTX Topco Ltd	$29.2K	13,342
MORGAN STANLEY	$4.5K	2,047
Tower Research Capital LLC (TRC)	$3.5K	1,611
UBS Group AG	$2.0K	895
GROUP ONE TRADING, L.P.	$31.00	14
BlackRock, Inc.	$22.00	10
Caitong International Asset Management Co., Ltd	$18.00	8

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AEMD on your watchlist

Track score changes the day AETHLON MEDICAL INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AEMD a good stock to buy?

13F Pro's AI-powered analysis of AETHLON MEDICAL INC (AEMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AEMD are available on the AEMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AEMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AEMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AETHLON MEDICAL INC's investment landscape.